Search Results

Voxtalisib 5 mg  | 99.36%

TargetMol

Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.

More Information Supplier Page

Voxtalisib 25 mg  | 99.36%

TargetMol

Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.

More Information Supplier Page

Ulixertinib 5 mg  | 99.89%

TargetMol

Ulixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.

More Information Supplier Page

Ulixertinib 25 mg  | 99.89%

TargetMol

Ulixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.

More Information Supplier Page

Ulixertinib 100 mg  | 99.89%

TargetMol

Ulixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.

More Information Supplier Page

Tubercidin 5 mg  | 98.66%

TargetMol

Tubercidin, an adenosine analogue, is a nucleoside antibiotic. It is incorporated into DNA and inhibits polymerases, thereby inhibiting DNA replication and RNA and protein synthesis. This agent also exhibits antifungal and antiviral activities.

More Information Supplier Page

MI-136 50 mg  | Purity Not Available

TargetMol

MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced.

More Information Supplier Page